Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer disposes of USD 1.34 million in common sharesPUBT·Jul 20 at 05:03 AMMPLT+3.22%
Maplight Therapeutics CMO Erin Pennock Foff sells USD 1.99 million in common sharesPUBT·Jul 17 at 08:44 PMMPLT+3.22%
Analyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target Amid Optimism for ML-007C-MATip Ranks·Jul 14 at 03:05 PMMPLT+3.22%
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLTrttnews·Jul 10 at 07:21 AMTRAX-6.59%MPLT+3.22%
Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR ReadoutTip Ranks·Jul 2 at 10:15 AMMPLT+3.22%
Maplight Therapeutics director Martin Babler files initial beneficial ownership statementPUBT·Jun 25 at 04:47 PMMPLT+3.22%
MapLight Therapeutics shareholders elect three directors at annual meetingPUBT·Jun 24 at 06:15 AMMPLT+3.22%
MapLight Therapeutics names Martin Babler, Troy Cox to board of directorsPUBT·Jun 24 at 06:01 AMMPLT+3.22%
Craig-Hallum Sticks to Its Buy Rating for MapLight Therapeutics, Inc. (MPLT)Tip Ranks·Jun 23 at 07:55 AMMPLT+3.22%
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescentsbenzinga_article·Jun 22 at 12:26 PMMPLT+3.22%
MapLight Therapeutics shares are trading higher after the company announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder.benzinga_article·Jun 22 at 10:44 AMMPLT+3.22%
